Kobayashi Hiroyuki, Arai Heii
Department of Neuropsychiatry, School of Medicine, Toho University, Ota-Ku, Tokyo, Japan.
Eisai Co., Ltd., Shinjuku-Ku, Tokyo, Japan.
Alzheimers Dement (N Y). 2018 Apr 9;4:130-136. doi: 10.1016/j.trci.2018.03.002. eCollection 2018.
Few studies have focused on the association between donepezil and physical comorbid conditions in Alzheimer's disease patients.
We investigated the association between donepezil prescription and the occurrences of comorbidities in Alzheimer's disease patients, by using an electronic medical records database which contains case-based information on approximately three million patients from more than 60 hospitals across Japan.
Nine thousand seven hundred forty-nine patients had at least one diagnosis of Alzheimer's disease between 2001 and 2015. To test the robustness of the results, we used a risk set sampling method, and the matched cohorts based on age, sex, comorbidity level, and duration of illness consisted of 1406 cases and an equal number of controls. From the multivariate logistic regression analysis adjusted for covariance, less occurrence of physical comorbidities was associated with donepezil prescription in the matched cohort.
Although the mechanisms are unknown, donepezil may have positive effects on both cognition and physical status.
很少有研究关注多奈哌齐与阿尔茨海默病患者身体合并症之间的关联。
我们通过使用一个电子病历数据库来调查多奈哌齐处方与阿尔茨海默病患者合并症发生情况之间的关联，该数据库包含来自日本60多家医院约300万患者的病例信息。
在2001年至2015年期间，9749名患者至少被诊断出患有阿尔茨海默病。为了检验结果的稳健性，我们使用了风险集抽样方法，基于年龄、性别、合并症水平和病程匹配的队列由1406例病例和同等数量的对照组成。在对协方差进行调整的多变量逻辑回归分析中，在匹配队列中，多奈哌齐处方与身体合并症发生率较低相关。
尽管机制尚不清楚，但多奈哌齐可能对认知和身体状况都有积极影响。
